Protara Therapeutics, Inc.
Protara Therapeutics, Inc. is a New York-based clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its pipeline centers on TARA-002, an investigational cell therapy, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, with development activities primarily in the United States.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInvestigational cell therapy being developed for non-muscle invasive bladder cancer and other oncology uses.
Development of TARA-002 for lymphatic malformations and related rare disease indications.
Investigational intravenous choline replacement therapy for patients receiving parenteral support.
Customers
Protara does not yet sell approved products, so its direct customers are future patients, physicians, and treatment centers that would use its therapies if approved. Its current stakeholders are clinical investigators, hospitals, and specialty care providers participating in trials for bladder cancer, lymphatic malformations, and parenteral support-related conditions.
Patients with non-muscle invasive bladder cancer and the urologists who would prescribe intravesical therapy if TARA-002 is approved.
Patients with lymphatic malformations and related maxillofacial cysts treated by pediatric surgeons and specialty clinicians.
Patients receiving nutrition and fluids through parenteral support who could use IV Choline Chloride if approved.
Hospitals and research centers that enroll patients, administer study drug, and generate clinical data for the pipeline.
Strategy
Protara’s strategy is to advance TARA-002 through clinical development in NMIBC and lymphatic malformations while preserving optionality for other rare disease uses. It is also developing IV Choline Chloride as a separate pipeline asset, using clinical data, regulatory progress, and intellectual property to build future commercialization opportunities.
Clinical proof-of-concept is the main value driver for a company with no approved products.
Successful approvals would create the basis for future partnering or commercialization.
Patent protection supports exclusivity in competitive oncology and rare disease markets.
Geography
Protara is headquartered in New York, and its development programs are managed from the United States. The company has secured worldwide rights to TARA-002 excluding Japan and Taiwan, so its commercial opportunity is global even though current operations are centered in U.S.-based clinical development.
Risks
Protara is exposed to the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory approval risk, and the need for ongoing external financing. Because it relies on third-party manufacturers and contractors, supply, quality, and execution issues can also disrupt development timelines and future commercialization.
- Clinical development failureImpact: CriticalLikelihood: Medium
The company’s value depends on positive data from TARA-002 and IV Choline Chloride trials.
Exposure: TARA-002 and IV Choline Chloride programs
- Regulatory approval riskImpact: HighLikelihood: High
Neither product candidate has FDA or other regulatory approval, so commercialization is not assured.
Exposure: All pipeline assets
- Financing riskImpact: HighLikelihood: High
The company has no current revenue and must fund ongoing R&D and trials externally.
Exposure: Corporate liquidity and development spend
- Third-party manufacturing and supply riskImpact: HighLikelihood: Medium
Clinical and future commercial supply depend on outside contractors and sole-source vendors.
Exposure - Competitive riskImpact: MediumLikelihood: Medium
Established therapies and better-capitalized developers compete in NMIBC and rare disease markets.
Exposure: NMIBC and oncology pipeline
Accounting
Judgemental itemsClinical trial and vendor costs are often recognized before cash settlement, requiring judgment on period-end accruals.
Impact: Can shift quarterly R&D expense and operating loss
As a public biotech, equity awards are a recurring non-cash expense in G&A and R&D.
Impact: Affects operating expenses and reported losses
With no product revenue, interest and investment returns are a visible component of other income.
Impact: Can partially offset operating losses
Similar listed companies
Publicly listed companies with a comparable business focus.
NuCana plc
NCNA · Pharmaceutical Preparations
NuCana plc is a clinical-stage biopharmaceutical company focused on developing cancer medicines based on its ProTide phosphoramidate chemistry platform.
ProQR Therapeutics N.V.
PRQR · Pharmaceutical Preparations
Protagenic Therapeutics, Inc.\new
PTIX · Pharmaceutical Preparations
Protagenic Therapeutics, Inc.
Lisata Therapeutics, Inc
LSTA · Pharmaceutical Preparations
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors.
Nkarta, Inc.
NKTX · Pharmaceutical Preparations
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Last updated: 24/09/2026